# PEA vs. Placebo for Major Depression

> **NCT06063369** · PHASE2 · UNKNOWN · sponsor: **The Israeli Medical Center for Alzheimer's** · enrollment: 100 (estimated)

## Conditions studied

- Bipolar Depression
- Major Depressive Disorder

## Interventions

- **DRUG:** Palmitoylethanolamide

## Key facts

- **NCT ID:** NCT06063369
- **Lead sponsor:** The Israeli Medical Center for Alzheimer's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-21
- **Primary completion:** 2023-12-21
- **Final completion:** 2024-12-21
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063369, "PEA vs. Placebo for Major Depression". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06063369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*